Toxicity & Resistance

Relevanta dokument
Antiretroviral Therapy: Current Status

WOMEN S INTERAGENCY HIV STUDY DRUG LIST 1 BY ALPHABET

6 februari Soffia Gudbjörnsdottir Registerhållare NDR

Measuring child participation in immunization registries: two national surveys, 2001

Adding active and blended learning to an introductory mechanics course

Hur fattar samhället beslut när forskarna är oeniga?

SPRING-2. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects. SE/HIV/0009/17k SE/HIV/0009/17k

Läkemedelsverkets Farmakovigilansdag

Validering av kvalitetsregisterdata vad duger data till?

FLAMINGO Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects

Dr Karla Rix-Trott Senior Medical Officer

Use of alcohol, tobacco and illicit drugs: a cause or an effect of mental ill health in adolescence? Elena Raffetti 31 August 2016

Tidig intervention vid typ-2 diabetes nya insikter från ADA och EASD 2015 en personlig reflektion

Bridging the gap - state-of-the-art testing research, Explanea, and why you should care

Skill-mix innovation in the Netherlands. dr. Marieke Kroezen Erasmus University Medical Centre, the Netherlands

Diabetes i ögat-vad är det som kan hända?? Monica Lövestam-Adrian

Skyddande av frågebanken

Professor Peter J Svensson Centre for Thrombosis and Haemostasis, SUS, Malmö

Klassificering av brister från internaudit

PORTSECURITY IN SÖLVESBORG

Dokumentnamn Order and safety regulations for Hässleholms Kretsloppscenter. Godkänd/ansvarig Gunilla Holmberg. Kretsloppscenter

SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects


Läkemedelsverkets riktlinjer Typ 2-diabetes, en behandlingsalgoritm

Uttagning för D21E och H21E

Barn med HIV Prognos, behandlingsindikationer, behandling Lars Navér

HOW DOES A DOLUTEGRAVIR BASED REGIMEN COMPARE TO ATRIPLA IN TREATMENT-NAÏVE PATIENTS?

Consumer attitudes regarding durability and labelling

Preschool Kindergarten

Familjär Hyperkolesterolemi

KOL med primärvårdsperspektiv ERS Björn Ställberg Gagnef vårdcentral

Uppdatering HIV-behandling. - Med lite regulatoriskt perspektiv. Olle Karlström Inf klin Karolinska-Huddinge Läkemedelsverket, Uppsala

JSL Socialstyrelsen. Migrationsverket. Information till dig som är gift med ett barn

Senaste trenderna från testforskningen: Passar de industrin? Robert Feldt,

SVENSK STANDARD SS-EN ISO 19108:2005/AC:2015

6 th Grade English October 6-10, 2014

Styrteknik: Binära tal, talsystem och koder D3:1

Beslut om bolaget skall gå i likvidation eller driva verksamheten vidare.

Pre exam I PATHOLOGY FOR MEDICAL STUDENTS

12.6 Heat equation, Wave equation

Resultat av den utökade första planeringsövningen inför RRC september 2005

Vad är värdet/faran med att operera tidigt? Sofia Strömberg Kärlkirurg Sahlgrenska Universitetssjukhuset

Questionnaire on Nurses Feeling for Hospital Odors

Strategy for development of car clubs in Gothenburg. Anette Thorén

The Algerian Law of Association. Hotel Rivoli Casablanca October 22-23, 2009

CHANGE WITH THE BRAIN IN MIND. Frukostseminarium 11 oktober 2018

FaR-nätverk VC. 9 oktober

Webbregistrering pa kurs och termin

- den bredaste guiden om Mallorca på svenska! -

Inkvarteringsstatistik. Göteborg & Co

Stiftelsen Allmänna Barnhuset KARLSTADS UNIVERSITET

8 < x 1 + x 2 x 3 = 1, x 1 +2x 2 + x 4 = 0, x 1 +2x 3 + x 4 = 2. x 1 2x 12 1A är inverterbar, och bestäm i så fall dess invers.

Metodprov för kontroll av svetsmutterförband Kontrollbestämmelse Method test for inspection of joints of weld nut Inspection specification

Inkvarteringsstatistik. Göteborg & Co

Vad innebär individualiserad behandling för äldre med typ 2-diabetes i praktiken?

Läkemedelsverkets Farmakovigilansdag 19 maj 2015

Health café. Self help groups. Learning café. Focus on support to people with chronic diseases and their families

Evidensbaserad medicin

Inkvarteringsstatistik. Göteborg & Co. Februari 2012

SAILING. Efficacy and safety of dolutegravir (DTG) in treatmentexperienced. SE/HIV/0009/17n SE/HIV/0009/17n SE/HIV/0009/17n

Schenker Privpak AB Telefon VAT Nr. SE Schenker ABs ansvarsbestämmelser, identiska med Box 905 Faxnr Säte: Borås

Isolda Purchase - EDI

1. Compute the following matrix: (2 p) 2. Compute the determinant of the following matrix: (2 p)

Materialplanering och styrning på grundnivå. 7,5 högskolepoäng

Affärsmodellernas förändring inom handeln

The lower the better? XIII Svenska Kardiovaskulära Vårmötet Örebro

Lipidsänkande behandling efter hjärtinfarkt - eller före? Kristina Hambraeus Överläkare, Cardiologkliniken Falu Lasarett

SVENSK STANDARD SS-ISO :2010/Amd 1:2010

Kvalitetsarbete I Landstinget i Kalmar län. 24 oktober 2007 Eva Arvidsson

SkillGuide. Bruksanvisning. Svenska

Följer vi SoS riktlinjer inom kranskärlssjukvården? Professor, överläkare Kardiologiska kliniken Universitetssjukhuset Linköping

State Examinations Commission

Accomodations at Anfasteröd Gårdsvik, Ljungskile

Att som sjuk arbeta i värme. (Tord Kjällström/Bruno Lemke, Nya Zeeland) Bengt Järvholm 13 juni 2017

EVALUATION OF ADVANCED BIOSTATISTICS COURSE, part I

Graviditetsdiabetes hälsokonsekvenser för mor och barn i ett längre perspektiv

Boiler with heatpump / Värmepumpsberedare

Pharmacovigilance lagstiftning - PSUR

BOENDEFORMENS BETYDELSE FÖR ASYLSÖKANDES INTEGRATION Lina Sandström

VIKING Efficacy and safety of dolutegravir in treatment-experienced subjects

Kombinerad träning kan muskeln bli snabb, stark och uthållig på samma gång?

Kurskod: TAIU06 MATEMATISK STATISTIK Provkod: TENA 17 August 2015, 8:00-12:00. English Version

Luftfartsavdelningen Sektionen för flygutbildning MANUALER VÄLKOMNA EN KORT SAMMANFATTNING AV INNEHÅLLET I RESPEKTIVE MANUAL

The role of X-ray imaging and musculoskeletal ultrasound in the diagnosis and management of rheumatoid arthritis

Sveriges internationella överenskommelser

District Application for Partnership

Syns du, finns du? Examensarbete 15 hp kandidatnivå Medie- och kommunikationsvetenskap

Proposition till Klubbmötet Regler för Tollarspecialens Tollarmästare och Juniortollarmästare

Webbreg öppen: 26/ /

Utvärdering av IVIG behandling vid post-polio syndrom. Kristian Borg

Oförstörande provning (NDT) i Del M Subpart F/Del 145-organisationer

Komponenter Removed Serviceable

IGF-Systemet som diagnostiskt hjälpmedel. Kerstin Brismar. Inst för molekylär medicin och kirurgi, Karolinska Institutet

Bilaga 5 till rapport 1 (5)

Swedish adaptation of ISO TC 211 Quality principles. Erik Stenborg

Alias 1.0 Rollbaserad inloggning

Lösenordsportalen Hosted by UNIT4 For instructions in English, see further down in this document

Vilken P2Y12-hämmare till vilken patient? Svenska Kardiovaskulära Vårmötet 4-6 maj, 2011, Örebro

Make a speech. How to make the perfect speech. söndag 6 oktober 13

Transkript:

Toxicity & Resistance HIV[e]EDUCATION Dr. Guido van den Berk December 2009 Sint Maarten

PI NRTI NRTI + or (the NRTI backbone ) NNRTI

Combination of at least 3 drugs, usually: 2 NRTIs (the NRTI backbone ), plus: 1 NNRTI or 1-2 PIs Therapy with only one or two agents allows HIV to overcome therapy through resistance mutations

According to the November 2008 DHHS guidelines for the use of ART. Which of the following statements is true regarding initial ART: A. Zidovudine-lamivudine (Combivir) plus efavirenz B. Tenofovir-emtricitabine (Truvada) plus ritonavir (norvir) plus Darunavir C. Abacavir plus tenofovir plus lamivudine D. Stavudine plus lamivudine plus lopinavir-ritonavir Zidovudine-lam... 0% 0% 0% 0% Tenofovir-emtr... Abacavir plus... Stavudine plus...

A. Zidovudine-lamivudine (Combivir) plus efavirenz B. Tenofovir-emtricitabine (Truvada) plus ritonavir (norvir) plus Darunavir C. Abacavir plus tenofovir plus lamivudine D. Stavudine plus lamivudine plus lopinavir-ritonavir

Class specific Drug specific

Patients A,B and C recently started HAART : A) AZT, 3TC, Nevirapine B) Abacavir, 3TC, Lopinavir/ritonavir C) Tenofovir, Emtricitabin, Efavirenz Patient A develops anemia. What is the most probable cause? 1. AZT 2. 3tc 3. nevirapine

Patient A develops anemia. What is the most probable cause? 1. AZT 2. 3tc 3. nevirapine 0% 0% 0% AZT 3tc nevirapine

Patients A,B and C recently started HAART : A) AZT, 3TC, Nevirapine B) Abacavir, 3TC, Lopinavir/ritonavir C) Tenofovir, Emtricitabin, Efavirenz Patient A develops rash. What is the most probable cause? 1. azt 2. 3tc 3. nevirapine

Patient A develops rash. What is the most probable cause? 1. azt 2. 3tc 3. nevirapine 0% 0% 0% azt 3tc nevirapine

Patients A,B and C recently started HAART : A) AZT, 3TC, Nevirapine B) Abacavir, 3TC, Lopinavir/ritonavir C) Tenofovir, Emtricitabin, Efavirenz Patient B develops diarrhea. Which medicine is the most probable cause? 1. abacavir, 2. 3tc 3. lopinavir / ritonavir

Patient B develops diarrhea. Which medicine is the most probable cause? 1. abacavir, 2. 3tc 3. lopinavir / ritonavir 0% 0% 0% abacavir, 3tc lopinavir / ri...

Patients A,B and C recently started HAART : A) AZT, 3TC, Nevirapine B) Abacavir, 3TC, Lopinavir/ritonavir C) Tenofovir, Emtricitabin, Efavirenz Patient c develops night mares. What is the most probable cause? 1) his wife 2) tenofovir 2) emtricitabin 3) efavirenz

Patient c develops night mares. What is the most probable cause? 1. His wife 2. tenofovir 3. emtricitabin 4. efavirenz 0% 0% 0% 0% His wife tenofovir emtricitabin efavirenz

Patients A,B and C recently started HAART : A) AZT, 3TC, Nevirapine B) Abacavir, 3TC, Lopinavir/ritonavir C) Tenofovir, Emtricitabin, Efavirenz Patient C develops renal insufficiency. What is the most probable cause? 1) tenofovir 2) emtricitabin 3) efavirenz

Patient C develops renal insufficiency. What is the most probable cause? 1. tenofovir 2. emtricitabin 3. efavirenz 0% 0% 0% tenofovir emtricitabin efavirenz

Rash Nevirapine > Efavirenz Hepatotoxicity Nevirapine > Efavirenz Efavirenz: Psychogenic side effects Teratogenic effects

Синдром Стивенса-Джонсона 90

GI effects Lipodystrophy Lipoatropy dyslipidemia Insulin resistance, diabetes

Changes in fat distribution Subcutaneous fat wasting Fat accumulation intra-abdominal abdominal fat localised breast enlargement buffalo hump lipomata Metabolic complications Dyslipidemia Insulin resistance Objective measures (DEXA, CT) crucial End points should be considered separately Diabetes mellitus (rare)

Lipoatrophy - hollow cheeks

Lipoatrophy - loss of subcutaneous fat in the legs of a woman 80

GI problems Mitochondrial toxicity with: Lactic acidosis Myelopathy (Cardio) myopathy Distal polyneuropathy ( d-drugs ) Pancreatitis Hepatitis Lipodystrophy

Nucleoside action in mitochondria N O R M A L Polymerase -Gamma Proteins encoded by mtdna mtdna mtdna ndna N R T I s mtdna mtdna ndna Brinkman K et al. Lancet 1999; 354: 1112-1115

Neuropathy Myopathy Cardiomyopathy Pancreatitis Hepatitis Lactic acidosis Bone marrow depression ZDV 3TC D 4 T DDC DDI ++ ++ ++ ++ + + + + + + ++ + + + + +/- + + ++ +/- + +

Events PYFU Incidence of Myocardial Infarction according to cart Exposure MIs per 1000 PY (95% CI) NEJM April 2007 8 7 6 5 4 3 2 1 0 None <1 1-2 2-3 3-4 4-5 5-6 6-7 >7 cart-exposure (yrs) RR per year of cart: Univariable: 1.16 [1.11-1.21] Adjusted: 1.16 [1.09-1.23] 16 17 20 41 61 62 51 47 30 11815 7105 9027 12098 14892 14394 11351 7935 5853 Total 345 94469

8 Relative Rate of MI according to PI Exposure Adjusted for NNRTI Adjusted RR* per year of PI: 1.16 [1.10-1.23] RR (95% CI) 4 2 1 0.5 None <1 1-2 2-3 3-4 4-5 5-6 >6 PI-Exposure (yrs) : Adjusted for sex, age, cohort, calendar year, prior CVD, family history of CVD, smoking, body-mass index, NNRTI exposure

8 Relative Rate of MI according to NNRTI Exposure Adjusted for PI RR (95% CI) 4 2 1 Adjusted RR* per year of NNRTI: 1.05 [0.98-1.13] 0.5 None <1 1-2 2-3 3-4 >4 NNRTI-Exposure (yrs) : Adjusted for sex, age, cohort, calendar year, prior CVD, family history of CVD, smoking, body-mass index, PI exposure

Effect of Exposure to PI and NNRTI before and after Adjusting for Lipids PI exposure (per additional year) RR 1.16 RR 1.10 NNRTI exposure (per additional year) RR 1.05 RR 1.00 0.9 1.0 1.1 1.2 1.3 Relative Rate of MI (95% CI) : Adjusted for sex, age, cohort, calendar year, prior CVD, family history of CVD, smoking, body-mass index, the other drug class Friis-Møller et al NEJM 2007

33.347 patiënts (157.912 patiënt years) 517 first myocardial infarction Out of the 517, in the 6 months before MI: 192 used abacavir 124 used ddi TA`s not associated with increased risk MI Recent (<6 mnths) or current abc or ddi use associated with higher risk MI Higher risk no longer observed in patients who had discontinued abc or ddi > 6 months Sabin CA et al. Lancet april 2008

ZDV ddi CHD (n = 639) Stroke (n = 195) RR: 1.40 (P =.005) d4t 3TC ABC RR: 1.63 (P =.0001) 0.50 0.75 1.00 1.25 1.50 1.75 2.00 Adjusted Relative Rate (95% CI) 2.25 Sabin CA et al. Lancet april 2008

Sabin CA et al. Lancet april 2008

EMEA : After examination of all currently available data, the EMEA and the national competent authorities have considered that, presently, no definitive conclusion can be drawn on the potential association between abacavir or didanosine use and the risk of myocardial infarction FDA: The FDA has stated that it regards the D:A:D study findings as incomplete as they did not include an analysis of abacavir s chief competitor, tenofovir (Viread), nor another important antiretroviral drug, FTC (emtricitabine, Emtriva)

RR 95% CI ddi d4t ddi / d4t ddi / HU d4t / ddi / HU 1.00 1.40 1.89 7.80 2.11 0.40 4.90 0.47 7.57 1.74 34.92 0.56 13.53

Neurotoxic agents d-drugs (ddc, ddi, d4t) Isoniazid, dapsone, vincristine Diabetes mellitus Alcoholism Vitamin B12 deficiency (rare)

Pinprick Normal Diminished Lost Hyperesthesia contact sensitivity or normal knee reflexes Strength normal ankle reflexes pin, temperature, vibration

The common reasons to switch: Toxicity Virological failure

Causes of treatment failure include: Patient factors (CD4 nadir, comorbidities) Drug resistance Suboptimal adherence ARV toxicity and intolerance Pharmacokinetic problems Suboptimal drug policy

Virologic failure: HIV RNA >400 copies/ml after 24 weeks >50 copies/ml after 48 weeks >400 copies/ml after viral suppression Immunologic failure: Failure to achieve and maintain adequate CD4 increase despite virologic suppression

Resistance

????

Most copies of HIV are the same in the body Part of HIV will be naturally resistant to ARV

General principles: Add at least 2 (preferably 3) fully active agents to an optimized background ARV regimen Determined by ARV history and resistance testing 1 active drug should not be added to a failing regimen (drug resistance is likely to develop quickly)

3TC has a unique mutation, M184V, which is commonly seen when failing regimen with 3TC A single mutation is enough to significantly decrease 3TC antiviral effect If mutation M184V is present emtricitabine is also failing (identical mutation) AZT and d4t have almost identical mutations and universal cross resistance K65R (Tenofovir resistance)

The K103N or Y188L mutation alone prevents the clinical utility of all NNRTIs NVP and EFV have universal cross resistance NVP or EFV should not be part of second line regimen after failing NNRTI first line treatment